Globeflex Capital L P Trims Position in OraSure Technologies, Inc. (OSUR)

Globeflex Capital L P decreased its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 71.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 68,731 shares of the medical instruments supplier’s stock after selling 168,333 shares during the period. Globeflex Capital L P owned 0.12% of OraSure Technologies worth $1,186,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in OSUR. BlackRock Inc. boosted its position in OraSure Technologies by 127,593.4% during the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock valued at $100,123,000 after purchasing an additional 7,737,261 shares during the last quarter. Vanguard Group Inc. boosted its position in OraSure Technologies by 30.3% during the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after purchasing an additional 1,037,439 shares during the last quarter. Renaissance Technologies LLC boosted its position in OraSure Technologies by 22.3% during the first quarter. Renaissance Technologies LLC now owns 5,132,003 shares of the medical instruments supplier’s stock valued at $66,357,000 after purchasing an additional 934,700 shares during the last quarter. JPMorgan Chase & Co. boosted its position in OraSure Technologies by 127.2% during the first quarter. JPMorgan Chase & Co. now owns 1,573,586 shares of the medical instruments supplier’s stock valued at $20,347,000 after purchasing an additional 881,132 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in OraSure Technologies by 32.5% during the second quarter. Acadian Asset Management LLC now owns 1,846,854 shares of the medical instruments supplier’s stock valued at $31,877,000 after purchasing an additional 452,642 shares during the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Globeflex Capital L P Trims Position in OraSure Technologies, Inc. (OSUR)” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/26/globeflex-capital-l-p-trims-position-in-orasure-technologies-inc-osur.html.

In other OraSure Technologies news, CFO Ronald H. Spair sold 510,112 shares of the stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $20.66, for a total value of $10,538,913.92. Following the transaction, the chief financial officer now directly owns 208,606 shares of the company’s stock, valued at approximately $4,309,799.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Brian Smith sold 9,112 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $20.47, for a total transaction of $186,522.64. Following the completion of the transaction, the insider now directly owns 32,477 shares in the company, valued at $664,804.19. The disclosure for this sale can be found here. Over the last three months, insiders sold 669,678 shares of company stock worth $13,886,419. Insiders own 6.40% of the company’s stock.

OSUR has been the subject of a number of research reports. Stephens reissued an “overweight” rating and set a $19.00 price objective (up previously from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. BidaskClub cut OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Canaccord Genuity reissued a “buy” rating and set a $22.00 price objective on shares of OraSure Technologies in a research report on Tuesday, September 19th. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Saturday, September 9th. Finally, Jefferies Group LLC lifted their price objective on OraSure Technologies from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, June 28th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $18.04.

OraSure Technologies, Inc. (NASDAQ:OSUR) opened at 22.14 on Tuesday. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of 40.92 and a beta of 1.57. OraSure Technologies, Inc. has a 12-month low of $7.09 and a 12-month high of $22.25. The firm’s 50-day moving average price is $20.72 and its 200 day moving average price is $16.18.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.02. The firm had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The business’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.07 EPS. On average, equities research analysts expect that OraSure Technologies, Inc. will post $0.48 EPS for the current fiscal year.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply